|
ARL6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.07980000391339E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
9.653800E-02 |
| Stage1-vs-Stage3 |
2.812100E-02 |
| Stage1-vs-Stage4 |
5.483800E-03 |
| Stage2-vs-Stage3 |
2.764000E-03 |
| Stage2-vs-Stage4 |
3.564300E-04 |
| Stage3-vs-Stage4 |
2.919000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.99119999564491E-08 |
| Normal-vs-Asian |
7.57660600925192E-12 |
| Caucasian-vs-AfricanAmerican |
3.365200E-01 |
| Caucasian-vs-Asian |
4.027600E-01 |
| AfricanAmerican-vs-Asian |
7.545400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.924300E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.85035999999972E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.496200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.853000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.016600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.977800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.806800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.929200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.68720000000211E-05 |
| Classical-VS-Follicular |
1.618890E-03 |
| Classical-VS-Other |
6.807000E-01 |
| Classical-VS-Normal |
3.99680288865056E-14 |
| Tall-VS-Follicular |
1.531700000168E-08 |
| Tall-VS-Other |
1.272760E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
1.865610E-01 |
| Follicular-VS-Normal |
4.71359999920651E-08 |
| Other-VS-Normal |
1.800510E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.44249065417534E-15 |
| N0-vs-N1 |
7.371500E-02 |
|
|
